Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
https://www.anavex.com/anavex-life-...he-treatment-of-adult-patients-with-rett-syn/
ANAVEX MEETS ENDPOINTS PHASE2 RETT
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.09 |
Change
0.070(0.37%) |
Mkt cap ! $2.431B | |||
| Open | High | Low | Value | Volume |
| $19.20 | $19.28 | $18.55 | $7.709M | 407.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 170 | $19.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.10 | 306 | 5 |
View Market Depth
| Last trade - 15.12pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.14 |
Change
0.070 ( 0.33 %) |
||||
| Open | High | Low | Volume | ||
| $19.12 | $19.26 | $18.55 | 113961 | ||
| Last updated 15.30pm 05/06/2024 ? | |||||
| NEU (ASX) Chart |